



Preparation of Analytical Standard of Bisoprolol Impurity A

Elżbieta Dąbrowska-Maś^{1*}

¹ICN Polfa Rzeszów S.A., 35-959 Przemysłowa 2, Poland.

Author's contribution

The sole author designed, analyzed and interpreted and prepared the manuscript.

Article Information

DOI: 10.9734/IRJPAC/2017/35656

Editor(s):

- (1) Chunyang Cao, State Key Laboratory of Bioorganic and Natural Product Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, China.
(2) Ichiro Imae, Division of Chemistry and Chemical Engineering, Hiroshima University, Japan.

Reviewers:

- (1) Manohar V. Lokhande, Sathaye College, India.
(2) Otávio Augusto Chaves, Universidade Federal Do Rio De Janeiro, Brazil.
Complete Peer review History: <http://www.sciedomains.org/review-history/20475>

Short Research Article

Received 24th July 2017
Accepted 5th August 2017
Published 11th August 2017

ABSTRACT

Aims: Research of the convenient method for obtaining (RS)-1-(4-Hydroxymethyl-phenoxy)-3-isopropylaminopropan-2-ol, known as the Impurity A of Bisoprolol, of high purity as close as 100%.

Study Design: Impurity A may be formed as a by-product in the processes used for commercial synthesis of bisoprolol fumarate. Impurity A may be also formed as a result of degradation (hydrolysis) of active substance. This compound is available as the reference standard, but the offered purity is between 95% and 97%, what suggest that its purification to the pharmaceutical quality is demanding. The most common method of purification of chemical standards for pharmacy is preparative chromatography and is commonly used for obtaining the reference standards of high purity, but it is unattainable in many cases, so there is a need for simple, convenient and repeatable laboratory procedures elaboration.

Place of Study: ICN Polfa Rzeszów S.A., Poland, Synthesis Laboratory.

Methodology: The synthesis of Bisoprolol Impurity A was performed starting from p-hydroxybenzyl alcohol and subsequent reactions with epichlorohydrin and isopropylamine, whereas purification process consisted particularly of obtaining and isolation of fumarate salt of Impurity A, its crystallization and basification.

Results: The analytical standard of Bisoprolol Impurity A of a purity of 95.5% was obtained with convenient chemical process without need of any advanced methodology. The structure was

*Corresponding author: E-mail: Elzbieta.DabrowskaMas@valeant.com;

elucidated with IR, NMR and EA methods and the purity was determined by HPLC technique.
Conclusion: The method of obtaining the analytical standard of Impurity A of purity as close as 100% is described in this paper.

Keywords: *Bisoprolol fumarate; impurity A reference standard; convenient purification.*

ABBREVIATIONS

API : Active Pharmaceutical Ingredient
HPLC : High Performance Liquid Chromatography
EP : European Pharmacopoeia
EA : Elemental Analysis
NMR : Nuclear Magnetic Resonance
MS : Mass Spectroscopy
Rel. S.D. : Relative Standard Deviation
SD : Standard Deviation
SMB : Simulated Moving Bed
TLC : Thin Layer Chromatography

1. INTRODUCTION

Active pharmaceutical ingredients (API) and the drug products should fulfil the regional registration requirements. In the European Union such the requirements are common and as regards the acceptable content of impurities (relative substances), the guidelines Q3A(R2) [1] and Q3B(R2) [2] for active substances and drug products respectively were adapted. Relative substances in drug substances and drug products, according to the mentioned guidelines, are divided into: degradation products, unreacted raw materials, intermediates and process impurities originated from raw materials, and finally by-products. Additionally, relative substances in drugs, drug substances and also excipients are divided into specified (characterised by chromatographic factors as retention time or retardation factor) and unspecified. The specified impurities can be subsequently divided into identified and unidentified [1,2]. Following the rules, the identified impurity content can be determined with the analytical method and converted on the known amount of reference standard, i.e. specified impurity or other substance used as a reference. The reference standard for determination of the impurity can be both pure chemical compound or a mixture of known percentage composition. The content of the chemical compound used as the reference standard in pharmacy should be as close as 100%.

The basic purification methods in chemical art, as repeatable crystallization, rectification or

extraction, are not sufficiently effective in many cases and obtaining chemical substance of high quality may not be possible, and more advanced techniques may be required.

The most effective method of purification in chemistry is chromatography, used to separate an individual compound from the mixture, but the disadvantage of advanced chromatographic techniques is that the special and expensive equipment is required. The column chromatography (flash chromatography) is frequently used for purification [3-5], but the modern chromatographic methods as preparative HPLC [6-11] and preparative TLC are also suitable for separation of the reference quality material [12]. Less used methods as simulated moving bed (SMB) could be the costless alternative [3,13] to the chromatographic techniques.

Reference standards of impurities (related substances) for drugs analysis both pharmacopoeial and non pharmacopoeial are widely available on the market, but the methods of synthesis and purification are not described in a great majority. The convenient methods of purification [14] of the reference standards are cost effective alternative, in comparison to the chromatographic techniques described above, but they are rather sparsely used.

Bisoprolol fumarate is a β_1 -selective adrenoceptor blocking agent marketed as the racemate, where the S-isomer is responsible for majority of the β_1 -blocking activity. The major impurity of this active substance is a racemic compound (RS)-1-(4-hydroxymethyl-phenoxy)-3-isopropylaminopropan-2-ol, known as specified Impurity A according to European Pharmacopoeia (EP).

Bisoprolol Impurity A is a by-product which may be formed in the most common synthesis processes of bisoprolol fumarate, i.e. according to Jonas [15,16] (see Fig. 1) and according to O'Neill [17] methods (see Fig. 2).

Impurity A is also a degradation product of bisoprolol hydrolysis (see Fig. 3).




Fig. 1. Scheme of possible formation of Impurity A in the synthesis of bisoprolol according to Jonas




Fig. 2. Scheme of possible formation of Impurity A in the synthesis of bisoprolol according to O'Neill




Fig. 3. Scheme of possible formation of impurity A in the hydrolysis of bisoprolol




Fig. 4. Scheme of possible formation of impurity A in hydrogenation of impurity L

Probably the most inconvenient impurity derived from the process and degradation of bisoprolol is 4-[(2RS)-2-hydroxy-3-(isopropylamino)propyl]oxy]benzaldehyde (see Fig. 4), known as Impurity L according to EP. This impurity removal from API is very difficult with simple methods, that is why it is often removed *via* formation of chemical derivatives. For example, impurity L may be simply hydrogenated with sodium borohydride [18], but this process is the next possible source of Impurity A (see Fig. 4). Impurity A can be removed from the

active substance through passing the post-reaction solution over a bed of neutral alumina [18].

2. MATERIALS AND METHODS

2.1 Synthesis Procedure of Crude Impurity A

24.4 g of p-hydroxybenzyl alcohol, 13.6 g of potassium carbonate and 37 mL of

epichlorohydrin was boiled for 5 hrs. The suspension was chilled and filtered. The filtrate was distilled under vacuum to obtain 32.0 g of yellow liquid. The product was reacted with 64.5 mL of isopropylamine for 3 days, under room temperature. After evaporation of excess reagent, the product in the amount of 40.6 g was dissolved in 120 mL of hot ethyl acetate and decolorized with 1.0 g charcoal activated. After crystallization the deposit was filtered and dried. 14.0 g of almost white solid was obtained.

2.2 Purification of Impurity A

The crude product was dissolved in the mixture of 70.0 mL of water and 3.7 g of fumaric acid. The solution was then mixed with charcoal activated, filtered and subsequently basified with sodium hydroxide. The precipitate was filtered and dried, next crystallized in 38 mL of acetone (filtered after dissolving). The product was dissolved in the mixture of 30 mL of acetone, 30 mL of isopropanol and 1.35 g of fumaric acid. After filtration the mixture was chilled and the precipitate filtered. Subsequently the solid product was neutralized with sodium hydroxide in water. The product was filtered, washed with water and methylene chloride. 3.37 g of the product was obtained.

2.3 HPLC Procedure for Purity Determination

The procedure applied for determination of purity of Bisoprolol Impurity A:

Stationary phase: Octadecyl modified silica
100-5 C18, 5 μ m, 4.6 x
250 mm

Mobile phase: Methanol (4 volumes) +
Phosphate buffer pH 5.5
(6 volumes)

Flow rate: 1.0 ml/min

Detector: UV 225 nm

Temperature: 50 \pm 2 $^{\circ}$ C

Sample volume: 10 μ l

3. RESULTS AND DISCUSSION

The synthesis and purification of Impurity A was performed according to the route presented on Fig. 5. Although the pathway of Impurity A formation in Jonas synthesis process was suggested by Khan, and in his work the presence of this impurity in Bisoprolol was confirmed with MS analysis [16], the synthesis of this compound is not described in art, as well as the way of its purification.

The synthesis was performed starting from p-hydroxybenzyl alcohol and excess epichlorohydrin in basic environment. The obtained epoxide was then reacted with excess isopropylamine. Impurity A thus synthesised was initially purified from coloured impurities thorough dissolving in ethyl acetate and treating with activated charcoal.

The purification method of Impurity A consisted firstly of formation of a salt with fumaric acid, which was soluble in water in opposite to unreacted traces of p-hydroxybenzyl alcohol. The second step of purification was basification and here residual reagents epichlorohydrin and isopropylamine were removed as soluble in filtrate. The obtained product was then dissolved in warm acetone, filtered (at this step all possible process inorganic impurities were removed) and finally crystallized. The last step of purification was obtaining afresh fumarate salt, but instead of water – in a mixture of organic solvents (equal volume of acetone and isopropanol), which was next crystallized to dispense with organic by-products. The last step was again basification and final washing.

The structure of the compound was elucidated by EA (see Table 1), NMR (see Table 2 and Fig. 6), MS (see Table 3 and Fig. 7) techniques and Infrared spectroscopy (wavenumbers in cm^{-1} : 3334, 3285, 3103, 3047, 2952, 2926, 2831, 1617, 1584, 1519, 1481, 1257, 1083, 1033, 834, 638).

The purity of Bisoprolol Impurity A was determined with HPLC method (see Fig. 8).

Table 1. Elemental analysis of impurity A

Element	Detected, %	S.D.	% Rel. S.D.	Variance	Calculated, %
Carbon	66.09	6.32E-03	9.57E-03	4.00E-05	65.25
Hydrogen	8.79	5.54E-02	0.6300	3.07E-03	8.84
Nitrogen	5.40	5.28E-02	0.9781	2.78E-03	5.85
Oxygen	19.11	0.0682	0.3568	4.65E-03	20.06




Fig. 5. Scheme of synthesis and purification of Bisoprolol Impurity A

Table 2. ^1H NMR analysis of Impurity A (50 mg in 1 mL)

Group	Chemical shift, ppm	Multiplicity	Integration
a	0.877, 0.955	doublet	6H
b	1.20 ÷ 2.40	broad	1H
c + d	2.426 ÷ 2.807	multiplet	3H
e + f	3.826	singlet	3H
g	4.369	singlet	2H
h + i	4.953	singlet	2H
j	6.783, 6.891	doublet	2H
k	7.135, 7.243	doublet	2H

Table 3. MS analysis of Impurity A (fragmentation)

Mass	Attribution
239	$[\text{M}]^+$
224	$[\text{M}]^+ - [\text{CH}_3]$
195	$[\text{M}]^+ - [\text{CH}_3, \text{C}_2\text{H}_5]$
153	$[\text{M}]^+ - [\text{CH}_3, \text{C}_2\text{H}_5, \text{C}_2\text{H}_4\text{N}]$
109	$[\text{M}]^+ - [\text{CH}_3, \text{C}_2\text{H}_5, \text{C}_2\text{H}_4\text{N}, \text{CH}_2\text{OH}, \text{CH}]$
93	$[\text{M}]^+ - [\text{CH}_3, \text{C}_2\text{H}_5, \text{C}_2\text{H}_4\text{N}, \text{CH}_2\text{OH}, \text{CH}, \text{O}]$




Fig. 6. ¹H NMR spectrum of Impurity A





Fig. 7. MS fragmentation spectrum of Impurity A



Detector A (225nm)					
Pk #	Retention Time	Area	Area %	Height	Height %
1	3,293	43624	0,186	5038	0,316
2	4,057	23437054	99,665	1585037	99,547
3	4,937	35151	0,149	2176	0,137

Fig. 8. Chromatogram of Impurity A

4. CONCLUSION

The possible pathway of formation of (RS)-1-(4-hydroxymethyl-phenoxy)-3-isopropyl-aminopropan-2-ol (Impurity A) in the Jonas synthesis of bisoprolol is known [16], but the process of obtaining the reference standard of this substance, especially of the purity as close as 100%, is not yet described. Moreover, the fumarate salt of Bisoprolol Impurity A is not mentioned anywhere, even though in the context of purification of Impurity A.

The proposed process of synthesis and purification of Bisoprolol Impurity A reference standard to the purity of 99.5% is efficient and cost-effective in comparison to the chromatographic techniques e.g. preparative TLC or preparative HPLC, it is also less laborious than SMB method. The crude compound may be purified to the purity of not less than 99.5% using simple, convenient and useful method.

COMPETING INTERESTS

Author has declared that no competing interests exist.

REFERENCES

1. ICH Topic Q 3 A (R2) Impurities in new Drug Substances. Available: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002675.pdf (June 4th 2017)
2. ICH Topic Q 3 B (R2) Impurities in New Drug Products. Available: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002676.pdf (June 4th 2017)
3. Prakash L, Himaja M, Ramakrishna Yadav B, Maheshwara Reddy A. Cost-effective isolation of a process impurity of pregabalin. *Sci. Pharm.* 2015;83:453-463. ([link](#))
4. Ahuja S, Mills Alsante K. Handbook of isolation and characterization of impurities in pharmaceuticals. Academic press. An imprint of Elsevier Science, San Diego, California; 2003. ([link](#))
5. Ahuja S, Scypinski S. Handbook of modern pharmaceutical analysis. Academic press. An imprint of Elsevier Science, San Diego, California; 2001. ([link](#))
6. Vijayakumar EKS, Gore VG, Mahajan A, Kumar M. Isolation and characterization of a process impurity in tizanidine hydrochloride. *Indian J Pharm Sci.* 2010; 72:360-362. ([link](#))
7. Li N, Yang J, Qin F, Li F, Gong P. Isolation and identification of a major impurity in a new bulk drug candidate by preparative LC, ESI-MS(n), LC-MS-MS, and NMR. *J Chromatogr Sci.* 2007;45-49. ([link](#))
8. Hiriyanna SG, Basavaiah K. Isolation and characterization of process related impurities in anastrozole active pharmaceutical ingredient. *J. Braz. Chem. Soc.* 2008;19:397-404. ([link](#))

9. Singh Rawat A, Buchude V, Chauhan K, Patel D, Patel R, Belwal C, Vardhan A. Identification, isolation and characterization of unknown impurity in daunorubicin hydrochloride. *Chemical Science Transactions*. 2013;3:1067-1077. ([link](#))
10. Sivakumar B. Identification and characterization of process related impurities of trans-resveratrol. *Scientia Pharmaceutica*. 2013;81:683-695. ([link](#))
11. Srinivasan V. Identification and characterization of process related impurities of trans-resveratrol. *Scientia Pharmaceutica*. 2011;79:555-568. ([link](#))
12. Desai S, Patel A, Gabhe SY. Isolation and characterization of impurities present in 8-chlorotheophylline. *Indian J Pharm Sci*. 2011;73:79–84. ([link](#))
13. Rajendran A, Paredes G, Mazzotti M. Simulated moving bed chromatography for the separation of enantiomers. *J Chromatogr A*. 2009;216:709-738. ([link](#))
14. Castelli E, Vailati A. 2006, WO2006004979. ([link](#))
15. Jonas R, Becker KH, Enenkel HJ, Minck K, Schliep HJ. US Pat. 4258062;1981. ([link](#))
16. Umar Khan Thesis. Studies on the synthesis of anti-hypertensive drug, Bisoprolol and analogs. Available:http://shodhganga.inflibnet.ac.in/bitstream/10603/101297/13/13_chapter%204.pdf (June 4th 2017)
17. O'Neill JA, Schickaneder H, Nikolopoulos A, Jas G. WO2010061366; 2010. ([link](#))
18. Arul R, Chauhan AD, Pathak RH, Agarwal R. WO2007069266; 2007. ([link](#))

© 2017 Dąbrowska-Maś; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

*The peer review history for this paper can be accessed here:
<http://sciencedomain.org/review-history/20475>*